3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
8
Phase 2
7
Phase 1/2
6
Phase 2/3
3
Phase 1
2
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Thoracic
1
Genitourinary
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Neuroblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
30
Magnetic Resonance Spectroscopy
23
Carboplatin
23
pembrolizumab
21
Paclitaxel
20
Gemcitabine
19
Specimen Handling
16
Dexamethasone
15
Radiotherapy
14
Nivolumab
14
Drug Therapy
14
Doxorubicin
14
Bevacizumab
14
atezolizumab
13
Oxaliplatin
13
Cyclophosphamide
13
Radiation
11
Pemetrexed
11
Cytarabine
11
venetoclax
10
Vincristine
10
Prednisone
10
Docetaxel
10
Capecitabine
10
Trastuzumab
9
Temozolomide
8
Rituximab
8
Platinum
8
Ipilimumab
8
Fluorouracil
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2/3
×
alectinib
×
1 year
×
Clear all
NCT03178552
2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3
Active not recruiting
1,000 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled